SecBot SecBot
8-K ·Filed May 5, 2026

XNCR

Xencor Inc
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001326732-26-000036
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

XmAb942 Phase 1 data supports best-in-class profile with 74-day half-life enabling Q12W SC dosing and low immunogenicity. The XENITH-UC Phase 2b blinded interim around YE26 is the next major catalyst. XmAb412 FIH start in 3Q26 adds pipeline optionality. Monitor for partnership interest given precedent valuations shown ($1.5B-$10B+).

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.85
T+0 close · May 5, 2026 · via day close
Latest settled
+67.24%
T+60 · $21.49
Vs SPY
+64.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $12.85entry
  2. T+1 · 7mo ago +1.25%α −0.14% · $13.01
  3. T+5 · 6mo ago −0.47%α −2.45% · $12.79
  4. T+20 · 6mo ago −12.76%α −17.72% · $11.21
  5. T+60 · 4mo ago +67.24%α +64.50% · $21.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days, favorable safety, and low immunogenicity (0% neutralizing antibodies at target dose). The company also presented preclinical data for XmAb412, a TL1A x IL23p19 bispecific, with predicted human half-life of 60-70 days. Enrollment in the Phase 2b XENITH-UC study remains on track with a blinded interim analysis expected around year-end 2026 and primary endpoint results in 2H27.

Key Facts

  • XmAb942 Phase 1 estimated terminal half-life of 74.1 days from pooled single-dose cohorts
  • 0% neutralizing antibodies (NAb+) at XENITH-UC target dose regimen; 25% ADA+ at target dose
  • 86% of patients predicted to achieve >99% TL1A inhibition at induction (Week 12) per QSP model
  • 90% of patients predicted to achieve >90% TL1A inhibition at maintenance (Week 52) with Q12W SC dosing
  • No serious or severe TEAEs; TEAE rates similar between XmAb942 (75%) and placebo (69%)
  • XmAb412 predicted human half-life of 60-70 days; NHP half-life >20 days
  • XmAb412 FIH study expected to begin 3Q26
  • XENITH-UC Phase 2b enrolling ~220 patients; blinded interim analysis ~YE26, primary endpoint 2H27
  • Cash position ~$611M as of Dec 31, 2025

Financial Impact

No financial data reported; clinical-stage biotech with ~$611M cash position

Risk Factors

  • Phase 2b XENITH-UC results may not replicate Phase 1 PK/PD predictions
  • Competitive landscape includes multiple first-gen anti-TL1A programs (afimkibart, tulisokibart, duvakitug) in Phase 3
  • ADA incidence of 57% across all doses could impact long-term efficacy if neutralizing antibodies emerge
  • No revenue-generating products; dependent on pipeline success and partnerships

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326732-26-000036
Document: xncr-20260504xexx992.htm0001326732-26-000036
Document: xncr-20260504.htm0001326732-26-000036
Document: 0001326732-26-000036-index-headers.html0001326732-26-000036
Document: 0001326732-26-000036-index.html0001326732-26-000036
Document: 0001326732-26-000036.txt0001326732-26-000036

Track record

20 reports on XNCR

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +49.10% at T+60 after the Aug 5, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
  3. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
  6. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
  7. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
  8. Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
  9. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026